JC-171

JC-171 is a selective NLRP3 inflammasome inhibitor, with an IC 50 of 8.45 μM for inhibiting LPS/ATP-induced interleukin-1β (IL-1β) release from J774A.1 macrophages. In Vitro JC-171 (0-100 μM) blocks NLRP3 inflammasome activation and IL-1β production in primary macrophages dose dependently. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: J774A.1 murine macrophage cells Concentration: 0-100 μM. Incubation Time: 0.5 h (before LPS (1 μg/mL) treatment for 4.5 h). Result: Inhibited the release of IL-1β in J774A.1 cells upon stimulation with LPS/ATP. In Vivo JC-171 treatment delays the progression and reduces the severity of experimental autoimmune encephalomyelitis (EAE) in mouse . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Mice immunized subcutaneously with 200 μg Myelin oligodendrocyte glycoprotein (MOG) 35–55 peptide emulsified in Complete Freund’s Adjuvant (CFA) on day 0 followed by injection of 200 ng of pertussis toxin. Dosage: 100 mg/kg, 10 mg/kg. Administration: IP days 0, 1 and 2; and every other days thereafter (100 mg/kg). Initiated when the clinical scores of individual mice have reached 1 (flaccid tail), and given every other day (10 mg/kg). Result: Efficiently suppressed EAE progression compared with vehicle treatment. Resulted in a substantial decrease in the frequency of MOG 35–55 -specific Th17 cells in the spleens and spinal cords of EAE mice. Form:Solid

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet